Difference between revisions of "Fluphenazine LA-Rest AP"

From Psychiatrienet
Jump to: navigation, search
 
Line 5: Line 5:
 
| start = {{StartOral afterDepot}}
 
| start = {{StartOral afterDepot}}
 
| info = {{caveQT}}
 
| info = {{caveQT}}
* the T<sub>1/2</sub> of fluphenazine depot is approximately 7-10 days.<ref> SmPC Anatensol Bristol-Myers Squibb B.V.</ref>
+
* the T<sub>1/2</sub> of fluphenazine depot is approximately '''7-10 days.'''<ref> SmPC Anatensol Bristol-Myers Squibb B.V.</ref>
  
 
}}
 
}}

Latest revision as of 15:18, 8 March 2024

Fluphenazine
long acting
Type Antipsychotic
Group Phenothiazines
links
Medscape Fluphenazine
PubChem 3372
PubMed Fluphenazine
Kompas (Dutch) Fluphenazine
Wikipedia Fluphenazine
{{:Rest AP[1] }}

Switch medication from Fluphenazine_LA to Rest AP[1].[2] [3]

Nietinrijdenbord.png Stop Fluphenazine_LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Rest AP[1]
  • t= 0 Start dosing 25% of the target dose on the day you normally would have injected the former depot.
  • t= 1 x T1/2 of depot approx. 50% of target dose
  • t= 2 x T1/2 of depot approx. 75% of target dose
  • t= 3 x T1/2 of depot approx. 100% of target dose
  • See 'more information' for the T1/2 of this depot
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[4]
  • the T1/2 of fluphenazine depot is approximately 7-10 days.[5]
  1. A. Risselada, Switchen van en naar depotantipsychotica - een update; Psyfar, june 2022 nummer 2
  2. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  3. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  4. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
  5. SmPC Anatensol Bristol-Myers Squibb B.V.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
[[Category:SwitchRest AP[1]]]